nach oben

Pituitary

Erschienen in:

08.09.2016

Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly

verfasst von: Nicholas A. Tritos, Beverly M. K. Biller

Erschienen in: Pituitary | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To review published data on pegvisomant and its therapeutic role in acromegaly.

Methods

Electronic searches of the published literature were conducted using the keywords: acromegaly, growth hormone (GH) receptor (antagonist), pegvisomant, therapy. Relevant articles (n = 141) were retrieved and considered for inclusion in this manuscript.

Results

Pegvisomant is a genetically engineered, recombinant growth hormone receptor antagonist, which is effective in normalizing serum insulin-like growth factor 1 (IGF-1) levels in the majority of patients with acromegaly and ameliorating symptoms and signs associated with GH excess. Pegvisomant does not have direct antiproliferative effects on the underlying somatotroph pituitary adenoma, which is the etiology of GH excess in the vast majority of patients with acromegaly. Therefore, patients receiving pegvisomant monotherapy require regular pituitary imaging in order to monitor for possible increase in tumor size. Adverse events in patients on pegvisomant therapy include skin rashes, lipohypertrophy at injection sites, and idiosyncratic liver toxicity (generally asymptomatic transaminitis that is reversible upon drug discontinuation), thus necessitating regular patient monitoring.

Conclusions

Pegvisomant is an effective therapeutic agent in patients with acromegaly who are not in remission after undergoing pituitary surgery. It mitigates excess GH action, as demonstrated by IGF-1 normalization, but has no direct effects on pituitary tumors causing acromegaly. Regular surveillance for possible tumor growth and adverse effects (hepatotoxicity, skin manifestations) is warranted.

Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951. doi:10.1210/jc.2014-2700 CrossRefPubMed

Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23(5):623–646. doi:10.1210/er.2001-0022 CrossRefPubMed

de Vos AM, Ultsch M, Kossiakoff AA (1992) Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255(5042):306–312CrossRefPubMed

Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA (1992) Rational design of potent antagonists to the human growth hormone receptor. Science 256(5064):1677–1680CrossRefPubMed

Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ (2005) Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 12(9):814–821. doi:10.1038/nsmb977 CrossRefPubMed

Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ (2006) New insights into growth hormone action. J Mol Endocrinol 36(1):1–7. doi:10.1677/jme.1.01933 CrossRefPubMed

Brooks AJ, Waters MJ (2010) The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol 6(9):515–525. doi:10.1038/nrendo.2010.123 CrossRefPubMed

Wang X, Darus CJ, Xu BC, Kopchick JJ (1996) Identification of growth hormone receptor (GHR) tyrosine residues required for GHR phosphorylation and JAK2 and STAT5 activation. Mol Endocrinol 10(10):1249–1260. doi:10.1210/mend.10.10.9121492 PubMed

Wang X, Xu B, Souza SC, Kopchick JJ (1994) Growth hormone (GH) induces tyrosine-phosphorylated proteins in mouse L cells that express recombinant GH receptors. Proc Natl Acad Sci U S A 91(4):1391–1395CrossRefPubMedPubMedCentral

10.

Chen WY, Wight DC, Wagner TE, Kopchick JJ (1990) Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci U S A 87(13):5061–5065CrossRefPubMedPubMedCentral

11.

Chen WY, Wight DC, Mehta BV, Wagner TE, Kopchick JJ (1991) Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol Endocrinol 5(12):1845–1852. doi:10.1210/mend-5-12-1845 CrossRefPubMed

12.

Chen WY, Chen NY, Yun J, Wagner TE, Kopchick JJ (1994) In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem 269(22):15892–15897PubMed

13.

Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK (2001) Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86(4):1716–1723. doi:10.1210/jcem.86.4.7403 PubMed

14.

Wilson ME (2000) Insulin-like growth factor I (IGF-I) replacement during growth hormone receptor antagonism normalizes serum IGF-binding protein-3 and markers of bone formation in ovariectomized rhesus monkeys. J Clin Endocrinol Metab 85(4):1557–1562. doi:10.1210/jcem.85.4.6522 PubMed

15.

Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennett WF (1999) Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 84(6):2098–2103. doi:10.1210/jcem.84.6.5732 PubMed

16.

Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342(16):1171–1177. doi:10.1056/NEJM200004203421604 CrossRefPubMed

17.

van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295):1754–1759CrossRefPubMed

18.

Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (2015) Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract 21(3):264–274. doi:10.4158/EP14330.OR CrossRefPubMedPubMedCentral

19.

Chanson P, Brue T, Delemer B, Caron P, Borson-Chazot F, Zouater H, Medecins de l’Etude, A (2015) Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY. Ann Endocrinol (Paris) 76(6):664–670. doi:10.1016/j.ando.2015.10.003 CrossRef

20.

Bernabeu I, Pico A, Venegas E, Aller J, Alvarez-Escola C, Garcia-Arnes JA, Marazuela M, Jonsson P, Mir N, Vargas MG, Spanish ACROSTUDY group (2016) Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary 19(2):127–137. doi:10.1007/s11102-015-0691-0 CrossRefPubMed

21.

Sievers C, Baur DM, Schwanke A, Buchfelder M, Droste M, Mann K, Stalla GK (2015) Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort. Pituitary 18(6):916–923. doi:10.1007/s11102-015-0673-2 CrossRefPubMed

22.

Cannavo S, Bogazzi F, Colao A, De Marinis L, Maffei P, Gomez R, Graziano E, Monterubbianesi M, Grottoli S, Italian ACROSTUDY group (2015) Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. J Endocrinol Invest 38(10):1099–1109. doi:10.1007/s40618-015-0289-4 CrossRefPubMed

23.

Grottoli S, Maffei P, Bogazzi F, Cannavo S, Colao A, Ghigo E, Gomez R, Graziano E, Monterubbianesi M, Jonsson P, De Marinis L (2015) ACROSTUDY: the Italian experience. Endocrine 48(1):334–341. doi:10.1007/s12020-014-0393-9 CrossRefPubMed

24.

Droste M, Domberg J, Buchfelder M, Mann K, Schwanke A, Stalla G, Strasburger CJ (2014) Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur J Endocrinol 171(1):59–68. doi:10.1530/EJE-13-0438 CrossRefPubMed

25.

Parkinson C, Burman P, Messig M, Trainer PJ (2007) Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92(1):190–195. doi:10.1210/jc.2006-1412 CrossRefPubMed

26.

Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK (2000) Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 85(12):4712–4720. doi:10.1210/jcem.85.12.7017 PubMed

27.

Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM, Trainer PJ (2001) Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur J Endocrinol 145(4):451–456CrossRefPubMed

28.

Herman-Bonert VS, Zib K, Scarlett JA, Melmed S (2000) Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 85(8):2958–2961. doi:10.1210/jcem.85.8.6851 PubMed

29.

Oriola J, Lucas T, Halperin I, Mora M, Perales MJ, Alvarez-Escola C, de Paz MN, Soto GD, Salinas I, Julian MT, Olaizola I, Bernabeu I, Marazuela M, Puig-Domingo M (2013) Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur J Endocrinol 168(1):9–13. doi:10.1530/EJE-12-0457 CrossRefPubMed

30.

Galland F, Kamenicky P, Affres H, Reznik Y, Pontvert D, Le Bouc Y, Young J, Chanson P (2006) McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. J Clin Endocrinol Metab 91(12):4957–4961. doi:10.1210/jc.2006-0561 CrossRefPubMed

31.

Beckers A, Lodish MB, Trivellin G, Rostomyan L, Lee M, Faucz FR, Yuan B, Choong CS, Caberg JH, Verrua E, Naves LA, Cheetham TD, Young J, Lysy PA, Petrossians P, Cotterill A, Shah NS, Metzger D, Castermans E, Ambrosio MR, Villa C, Strebkova N, Mazerkina N, Gaillard S, Barra GB, Casulari LA, Neggers SJ, Salvatori R, Jaffrain-Rea ML, Zacharin M, Santamaria BL, Zacharieva S, Lim EM, Mantovani G, Zatelli MC, Collins MT, Bonneville JF, Quezado M, Chittiboina P, Oldfield EH, Bours V, Liu P, WdH W, Pellegata N, Lupski JR, Daly AF, Stratakis CA (2015) X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer 22(3):353–367. doi:10.1530/ERC-15-0038 CrossRefPubMedPubMedCentral

32.

Creo AL, Lteif AN (2016) Pituitary gigantism: a retrospective case series. J Pediatr Endocrinol Metab 29(5):597–602. doi:10.1515/jpem-2015-0269 CrossRefPubMed

33.

Goldenberg N, Racine MS, Thomas P, Degnan B, Chandler W, Barkan A (2008) Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. J Clin Endocrinol Metab 93(8):2953–2956. doi:10.1210/jc.2007-2283 CrossRefPubMedPubMedCentral

34.

Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B (2005) Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol 153(2):195–201. doi:10.1530/eje.1.01956 CrossRefPubMed

35.

Higham CE, Thomas JD, Bidlingmaier M, Drake WM, Trainer PJ (2009) Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol 161(1):21–25. doi:10.1530/EJE-08-0990 CrossRefPubMed

36.

Jehle S, Reyes CM, Sundeen RE, Freda PU (2005) Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab 90(3):1588–1593. doi:10.1210/jc.2004-1967 CrossRefPubMed

37.

Van der Lely AJ, Jonsson PJ, Wilton P, Akerblad AC, Cara J, Ghigo E (2016) Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY. Eur J Endocrinol. doi:10.1530/EJE-16-0008

38.

Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ (2007) Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol 156(3):315–319. doi:10.1530/eje.1.02341 CrossRefPubMed

39.

Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90(10):5684–5691. doi:10.1210/jc.2005-0331 CrossRefPubMed

40.

Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88(12):5650–5655. doi:10.1210/jc.2003-030772 CrossRefPubMed

41.

Trainer PJ, Drake WM, Perry LA, Taylor NF, Besser GM, Monson JP (2001) Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J Clin Endocrinol Metab 86(7):2989–2992. doi:10.1210/jcem.86.7.7664 PubMed

42.

Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, Martin NM, Moyes V, Newell-Price J, Trainer PJ (2012) Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab 97(4):1187–1193. doi:10.1210/jc.2011-2603 CrossRefPubMed

43.

Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders RA, Janssen JA, Buchfelder M, Hofland LJ, Jorgensen JO, van der Lely AJ (2014) Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab 99(10):3644–3652. doi:10.1210/jc.2014-2032 CrossRefPubMed

44.

van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Haggstrom M (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97(5):1589–1597. doi:10.1210/jc.2011-2508 CrossRefPubMed

45.

Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ (2006) Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol 154(6):805–806. doi:10.1530/eje.1.02160 CrossRefPubMed

46.

Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H, Strasburger CJ, German pegvisomant investigators (2006) Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 154(2):213–220. doi:10.1530/eje.1.02079 CrossRefPubMed

47.

Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE (2007) Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 92(9):3374–3377. doi:10.1210/jc.2007-0997 CrossRefPubMed

48.

van der Lely AJ, Gomez R, Heissler JF, Akerblad AC, Jonsson P, Camacho-Hubner C, Koltowska-Haggstrom M (2015) Pregnancy in acromegaly patients treated with pegvisomant. Endocrine 49(3):769–773. doi:10.1007/s12020-014-0508-3 CrossRefPubMed

49.

Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM (1997) Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276(5319):1706–1709CrossRefPubMed

50.

Flyvbjerg A, Bennett WF, Rasch R, Kopchick JJ, Scarlett JA (1999) Inhibitory effect of a growth hormone receptor antagonist (G120 K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 48(2):377–382CrossRefPubMed

51.

Dagnaes-Hansen F, Duan H, Rasmussen LM, Friend KE, Flyvbjerg A (2004) Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res 24(6):3735–3742PubMed

52.

Friend KE, Khandwala HM, Flyvbjerg A, Hill H, Li J, McCutcheon IE (2001) Growth hormone and insulin-like growth factor-I: effects on the growth of glioma cell lines. Growth Horm IGF Res 11(2):84–91. doi:10.1054/ghir.2000.0183 CrossRefPubMed

53.

Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21(3):215–244. doi:10.1210/edrv.21.3.0399 CrossRefPubMed

54.

McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, Friend KE (2001) Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 94(3):487–492. doi:10.3171/jns.2001.94.3.0487 CrossRefPubMed

55.

Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A (2007) Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 13(3):1000–1009. doi:10.1158/1078-0432.CCR-06-1910 CrossRefPubMed

56.

Evans A, Jamieson SM, Liu DX, Wilson WR, Perry JK (2016) Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model. Cancer Lett 379(1):117–123. doi:10.1016/j.canlet.2016.05.031 CrossRefPubMed

57.

Drake WM, Grossman AB, Hutson RK (2005) Effect of treatment with pegvisomant on meningioma growth in vivo. Eur J Endocrinol 152(1):161–162CrossRefPubMed

Titel: Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly
verfasst von: Nicholas A. Tritos
Beverly M. K. Biller
Publikationsdatum: 08.09.2016
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 1/2017
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-016-0753-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Epidemiology of acromegaly: review of population studies

The surgical treatment of acromegaly

Somatostatin receptor ligands in the treatment of acromegaly

Update on quality of life in patients with acromegaly

Updates in outcomes of stereotactic radiation therapy in acromegaly